FDA approves Stada's Lucentis biosimilar; Lilly claims its triple-G candidate outperforms Ozempic in diabetes
read at raps ↗ApprovalPositive
The U.S. Food and Drug Administration has granted approval for Stada's biosimilar version of Lucentis, expanding treatment options for eye diseases.
Lilly announced that its experimental "triple‑G" diabetes drug demonstrated better results than the existing therapy Ozempic in a comparative assessment.
Both developments could influence prescribing patterns and competitive dynamics in ophthalmology and diabetes care, offering clinicians additional choices for their patients.
source
This writeup was produced by pharmadog from original reporting by raps.
Original headline: “Recon: FDA approves Stada’s Lucentis biosimilar; Lilly says ‘triple-G’ candidate bests Ozempic in diabetes”
read at raps ↗
comments(0)
5-min edit window · permanent after that